

Newsletter

Issue 3, May 2013

ERICA: The Evaluation of the Role of Inflammation in Chronic Airways Disease


Multicentre Trial: Addenbrooke's Cambridge (Trial centre), Nottingham, Royal Brompton, Cardiff, and Edinburgh

**INTERIM Analysis (n=398, complete data sets) presented
6 month extension has been granted**

Brief points from TSB Q6 Meeting in Cambridge on April 25th 2013.


Current recruitment:

As of April 30, 2013, n = 506. Many thanks to ALL investigators and research staff who have persisted with identifying eligible patients and recruiting them to our trial. We greatly appreciate your time and commitment!



Recruitment numbers needed to reach target

ERICA has been given a 6 Month Extension:



- To aid recruitment, we've been given a 6 month no-cost extension
- Please carry on with current recruitment strategies to ensure target of n=800

Exacerbation Validation Phone Call:

- **Purpose of this phone call:**
 - Exacerbation is a very important criteria for data analysis. We would like to validate the answers patients provide in their Follow-Up questionnaire (Q17 & 18 of Follow Up Qu) to ensure they are answering /interpreting the questions correctly.
- We will randomly select patients who responded from March 2013 Questionnaire Mail Out (10 from all sites, 50, from Cardiff) and ask you to phone these patients and ask them a few questions about their health.
- The *Trial Coordinating Centre* will be in touch with the individual sites in the next couple of weeks about how to go about doing this.
- We would like to contact patients as soon as possible after the March 2013 Questionnaire responses
- We expect this phone call study to be completed by the end of May, latest, first week of June 2013.

Points from INTERIM Analysis:

- Interim data was presented and well received at the TBS Q6 meeting.
- The purpose of this preliminary analysis was to look at trends in the data, thus no conclusive statements were made
- From March 21st 2013 data download, recruitment was n = 465, with complete data from n = 398
- Still some attainable variables missing – like height and weight that need to be addressed by sites
- The purpose of the study is to look for associations between Fibrinogen and other variables of interest. It was found that there exist significant correlations between Fibrinogen and MRC score, SPPB score, 6MDW, and FEV₁%.
- There are distinct cardiovascular and skeletal muscle phenotypes in COPD patients. These appear to be prevalent and may require separate treatments.

THANK-YOU EVERYONE!!

ERICA Trial Contacts:

Trial Centre:

Dr. Mellone Marchong (Trial Coordinator)
Cambridge Clinical Trials Unit (CCTU)
University Hospitals NHS Foundation Trust ,
Addenbrooke's Hospital, Clinical School,
Level 3 - Box 111, Hills Road, Cambridge
CB2 0QQ
Tel: 01223 348 143
Fax: 01223 596 471
Email: mellone.marchong@addenbrookes.nhs.uk
Secure Email: mellone.marchong@nhs.net

Dr. Ian Wilkinson (Chief Investigator)
Addenbrooke's Hospital, Clinical Pharmacology Unit
Box 110, Hills Road, Cambridge CB2 0QQ
Tel: 01223 336 806
Email: ibw20@medschl.cam.ac.uk

Dr. Mike Polkey (PI/Clinical Co-lead Investigator)
Royal Brompton and Harefield NHS Trust
Department of Respiratory Medicine Fulham Road
London SW3 6NP
Tel: 027 351 8058
Email: m.polkey@rbht.nhs.uk